KHB(SZ:002022)2022-12-06 02:34Group 1: Company Performance and Strategy - The company experienced a decline in performance in Q1 due to inventory digestion in self-produced reagent sales, despite rapid growth in agency business [2] - The company aims to stabilize growth in the blood screening business in 2017, leveraging favorable policies and expanding terminal demand [3] - The gross profit margin decreased by 4 percentage points in 2016 due to the acquisition of TGS, which operates in lower-margin markets [2][3] Group 2: Product Development and Market Positioning - The company has entered over 10 provinces with its self-produced luminescent products and has registered more than 30 testing projects [3] - A strategic alliance with Biokit has been established for the next five years, focusing on the distribution of BioFlash systems and related products [3] - The company is committed to enhancing its chemical luminescence product competitiveness through ongoing R&D and registration efforts [4] Group 3: Financial Management and Cost Control - The company plans to control expenses through budget management and by monitoring changes in revenue structure [3] - Future acquisitions will focus on product and technology advantages, as well as sales revenue and profit contributions [4] Group 4: Organizational Structure and Market Strategy - The internal organizational structure has been adjusted to focus on product-centric and customer-oriented strategies, establishing new divisions for better efficiency [4] - The company is exploring channel mergers and partnerships to leverage product and brand advantages [4]